The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Open accessAbstract
Background: Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM). Methods: Recurrent GBM patients with ≤ 1 chemotherapy regimen for progressive disease were eligible. Temsirolimus was administered in a 250-mg intravenous dose weekly. Results: Sixty-five patients were treated. The incidence of grade 3 or higher nonhematologic toxicity was 51%, and consisted mostly of hypercholesterolemia (11%), hypertriglyceridemia (8%), and hyperglycemia (8%). Grade 3 hematologic toxicity was observed in 11% of patients. Temsirolimus peak concentration (C max), and sirolimus C max and area under the concentration-time curve were decreased in patients receiving p450 enzyme–inducing anticonvulsants (EIACs) by 73%, 47%, and 50%, respectively, but were still within the therapeutic range of preclinical models. Twenty patients (36%) had evidence of improvement in neuroimaging, consisting of decrease in T2 signal abnormality +/− decrease in T1 gadolinium enhancement, on stable or reduced steroid doses. Progression-free survival at 6 months was 7.8% and median overall survival was 4.4 months. Median time to progression (TTP) for all patients was 2.3 months and was significantly longer for responders (5.4 months) versus nonresponders (1.9 months). Development of grade 2 or higher hyperlipidemia in the first two treatment cycles was associated with a higher percentage of radiographic response (71% v 31%; P = .04). Significant correlation was observed between radiographic improvement and high levels of phosphorylated p70s6 kinase in baseline tumor samples (P = .04). Conclusion: Temsirolimus is well tolerated in recurrent GBM patients. Despite the effect of EIACs on temsirolimus metabolism, therapeutic levels were achieved. Radiographic improvement was observed in 36% of temsirolimus–treated patients, and was associated with significantly longer TTP. High levels of phosphorylated p70s6 kinase in baseline tumor samples appear to predict a patient population more likely to derive benefit from treatment. These findings should be validated in other studies of mTOR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
Self-citationGingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 772
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Self-citationThe rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
Self-citationAn inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
(1997) · PubMed · Cited by 512
Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Self-citationJenkins, R. B., Qian, J., Lieber, M. M., & Bostwick, D. G. (1997) · PubMed · Cited by 443
Self-citationThe prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S., & Ghosh, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0272 · Cited by 324
Self-citationImmunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.
Malik, S. N., Brattain, M. G., Ghosh, P., Troyer, D. A., Prihoda, T. J., Bedolla, R. G., & Kreisberg, J. I. (2002) · PubMed · Cited by 321
Self-citationDudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M. G., Arbuck, S. G., Travis, R., Sausville, E. A., & Houghton, P. J. (2001) · PubMed · Cited by 232
Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin
Huffman, T. A., Mothe-Satney, I., & Lawrence, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022634399 · Cited by 215
Eshleman, J. S., Carlson, B. L., Mladek, A. C., Kastner, B. D., Shide, K. L., & Sarkaria, J. N. (2002) · PubMed · Cited by 198
Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis
Hurt, M. R., Moossy, J., Donovan-Peluso, M., & Locker, J. (1992) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199201000-00010 · Cited by 197
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba, J. M., deGraffenried, L. A., Friedrichs, W. E., Fulcher, L. C., Grünwald, V., Weiss, G. R., & Hidalgo, M. M. (2003) · PubMed · Cited by 191
Self-citationOpposite Translational Control of GLUT1 and GLUT4 Glucose Transporter mRNAs in Response to Insulin
Taha, C., Liu, Z., Jin, J., Al‐Hasani, H., Sonenberg, N., & Klip, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.33085 · Cited by 188
Seufferlein, T., & Rozengurt, E. (1996) · PubMed · Cited by 169
Punt, C. J. A., Boni, J. P., Bruntsch, U., Peters, M. E. W. J., & Thielert, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg248 · Cited by 121
Self-citationTemozolomide in the treatment of recurrent malignant glioma
Chang, S. M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., & Prados, M. D. (2004) · Cancer · doi:10.1002/cncr.11949 · Cited by 90
Chemotherapy for high-grade gliomas
Galanis, E., & Langrish, V. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1075 · Cited by 79
Self-citationThe Role of Chemotherapy in Recurrent Malignant Gliomas: An Overview
Brandes, A. A., & Fiorentino, M. V. (1996) · Cancer Investigation · doi:10.3109/07357909609076900 · Cited by 67
Response and progression in recurrent malignant glioma
Hess, K. R., Wong, E. T., Jaeckle, K. A., Kyritsis, A. P., Levin, V. A., Prados, M. D., & Yung, W. K. A. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.4.282 · Cited by 56
Self-citationRecurrent malignant glioma in adults
Tatter, S. B. (2002) · Current Treatment Options in Oncology · doi:10.1007/s11864-002-0070-8 · Cited by 52
Vos, M. J., Hoekstra, O. S., Barkhof, F., Berkhof, J. H., Heimans, J. J., van Groeningen, C. J., Vandertop, W. P., Slotman, B. J., & Postma, T. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.001 · Cited by 46
Cited by
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
The roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Metadata
- Authors
- Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., Jaeckle, K. A., Scheithauer, B. W., Dancey, J., Hidalgo, M., & Walsh, D. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-10
- Volume
- 23
- Issue
- 23
- Pages
- 5294-5304
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114438728
- Cited by
- 694
- References
- 30
- FWCI
- 24.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.